Topical Drug Delivery to the Posterior Segment of the Eye.

Pharmaceutics · 2022 · PMC8779621 · PMID 35057030

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a Phase II trial ( NCT01678963 ), this formulation, with improved trans-scleral permeability and increased choroidal retention, showed a trend towards better visual acuity in patients with all types of naïve neovascular lesions.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.